Low-energy Linear Extracorporal Shock Wave Therapy for Erectile Dysfunction.
Launched by GRZEGORZ FOJECKI · Feb 12, 2014
Trial Information
Current as of June 28, 2025
Completed
Keywords
ClinConnect Summary
Erectile dysfunction has a negative impact on quality of life and relationships. Thirty to sixty- five percent of men over 40 years of age have erection disorders. Current challenges of medical treatment are met with high costs and risks of side effects. Emerging new therapy with low-energy shock waves stimulate production of endothelial growth factor and nitrogen oxide which results in angiogenesis. It is our aim to assess efficaciousness of this method on potential to improve erectile dysfunction. We propose a prospective double-blind, randomised, cross-over, sham-controlled trial, to ass...
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Erectile dysfunction for at least 6 months
- • In relationships
- • Patient accept not to use any other therapy against erectile dysfunction
- Exclusion Criteria:
- • Prostatectomy
- • Radiotherapy in pelvis
- • Hormonal therapy against prostate cancer
- • Anatomical penis disorder
- • Penile prosthesis
- • Treatment with anticoagulants (except acetylsalicylic acid 75 mg)
- • Psychiatric disorder
- • Hypogonadism
- • IIEF score higher than 25
- • Pregnant partner og delivered within last 12 months
- • Critical health disease
- • Neurological disorders
About Grzegorz Fojecki
Grzegorz Fojecki is a dedicated clinical trial sponsor specializing in the design and implementation of innovative clinical research studies. With a strong commitment to advancing medical science, Grzegorz Fojecki focuses on developing effective therapies and improving patient outcomes across various therapeutic areas. Leveraging a robust network of healthcare professionals and research institutions, the organization ensures rigorous adherence to regulatory standards and ethical practices. Their collaborative approach fosters the integration of cutting-edge methodologies, ultimately contributing to the acceleration of medical advancements and the enhancement of healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sonderborg, Southern Denmark, Denmark
Patients applied
Trial Officials
Palle Oshter, professor
Study Director
University of Southern Denmark
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials